• Je něco špatně v tomto záznamu ?

Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database

A. Poprach, K. Rumanova, R. Lakomý, R. Chloupková, M. Stanik, T. Pokrivcak, I. Kiss, O. Slaby, H. Studentova, B. Melichar, J. Juracek, O. Fiala, J. Kopecky, K. Kopeckova, M. Zemanova, T. Buchler,

. 2019 ; 37 (4) : 294.e1-294.e8. [pub] 20190123

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006622

BACKGROUND: Nonclear cell renal cell carcinoma (nccRCC) is a heterogeneous group of primary kidney tumors. The aim of the present retrospective study was to analyze outcomes of patients with nccRCC treated with tyrosine-kinase inhibitors (TKIs) based on a national registry. METHODS: The registry contained evaluable data of 93 nccRCC patients treated with first-line TKIs, including 87 patients with papillary renal cell carcinoma (RCC) and 6 patients with chromophobe RCC. The control cohort consisted of 1,788 patients with clear-cell RCC treated with first-line TKIs. Multivariable Cox proportional hazard model was used to evaluate the effect of potential prognostic factors on the survival measures. RESULTS: Median progression-free survival was 11.8 and 6.5 months in the clear cell renal cell carcinoma and nccRCC patients, respectively (P = 0.018), and median overall survival was 33.2 and 22.0 months, respectively (P = 0.007). In the multivariate analysis, independent factors associated with inferior progression-free survival included high tumor grade, worse Memorial Sloan Kettering Cancer Center risk group, absence of nephrectomy, and sunitinib (as opposed to pazopanib) as first-line targeted therapy. Independent predictors of inferior overall survival included nonclear cell histology, tumor grade, worse Memorial Sloan Kettering Cancer Center risk group, absence of nephrectomy, older age, and sunitinib as first-line targeted therapy. CONCLUSIONS: The present retrospective, registry-based study confirms that patients with nccRCC treated with TKIs have worse clinical outcomes compared to clear cell renal cell carcinoma patients with similar baseline characteristics.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006622
003      
CZ-PrNML
005      
20200526152347.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.urolonc.2018.12.017 $2 doi
035    __
$a (PubMed)30683455
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
245    10
$a Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database / $c A. Poprach, K. Rumanova, R. Lakomý, R. Chloupková, M. Stanik, T. Pokrivcak, I. Kiss, O. Slaby, H. Studentova, B. Melichar, J. Juracek, O. Fiala, J. Kopecky, K. Kopeckova, M. Zemanova, T. Buchler,
520    9_
$a BACKGROUND: Nonclear cell renal cell carcinoma (nccRCC) is a heterogeneous group of primary kidney tumors. The aim of the present retrospective study was to analyze outcomes of patients with nccRCC treated with tyrosine-kinase inhibitors (TKIs) based on a national registry. METHODS: The registry contained evaluable data of 93 nccRCC patients treated with first-line TKIs, including 87 patients with papillary renal cell carcinoma (RCC) and 6 patients with chromophobe RCC. The control cohort consisted of 1,788 patients with clear-cell RCC treated with first-line TKIs. Multivariable Cox proportional hazard model was used to evaluate the effect of potential prognostic factors on the survival measures. RESULTS: Median progression-free survival was 11.8 and 6.5 months in the clear cell renal cell carcinoma and nccRCC patients, respectively (P = 0.018), and median overall survival was 33.2 and 22.0 months, respectively (P = 0.007). In the multivariate analysis, independent factors associated with inferior progression-free survival included high tumor grade, worse Memorial Sloan Kettering Cancer Center risk group, absence of nephrectomy, and sunitinib (as opposed to pazopanib) as first-line targeted therapy. Independent predictors of inferior overall survival included nonclear cell histology, tumor grade, worse Memorial Sloan Kettering Cancer Center risk group, absence of nephrectomy, older age, and sunitinib as first-line targeted therapy. CONCLUSIONS: The present retrospective, registry-based study confirms that patients with nccRCC treated with TKIs have worse clinical outcomes compared to clear cell renal cell carcinoma patients with similar baseline characteristics.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a karcinom z renálních buněk $x farmakoterapie $x mortalita $x patologie $7 D002292
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a inhibitory proteinkinas $x farmakologie $x terapeutické užití $7 D047428
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rumanova, Kristina $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Lakomý, Radek $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Chloupková, Renata $u Institute of Biostatistics and Analyses, Faculty of Medcine, Masaryk University, Brno, Czech Republic.
700    1_
$a Stanik, Michal $u Department of Urologic Oncology, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Pokrivcak, Tomas $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Slaby, Ondrej $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Studentova, Hana $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Juracek, Jaroslav $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Fiala, Ondrej $u Department of Oncology, University Hospital, Pilsen, Czech Republic.
700    1_
$a Kopecky, Jindrich $u University Hospital in Hradec Králové, Hradec Králové, Czech Republic.
700    1_
$a Kopeckova, Katerina $u Department of Oncology, Motol University Hospital and Charles University Second Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Zemanova, Milada $u Department of Oncology, General University Hospital and Charles University First Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Thomayer University Hospital and Charles University, Prague, Czech Republic. Electronic address: tomas.buchler@ftn.cz.
773    0_
$w MED00008671 $t Urologic oncology $x 1873-2496 $g Roč. 37, č. 4 (2019), s. 294.e1-294.e8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30683455 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200526152343 $b ABA008
999    __
$a ok $b bmc $g 1525480 $s 1096678
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 37 $c 4 $d 294.e1-294.e8 $e 20190123 $i 1873-2496 $m Urologic oncology $n Urol Oncol $x MED00008671
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace